Bench2Bedside: How is EGB Ventures different from traditional venture capital firms?

William Garner: EGB Ventures is built around venture formation rather than simply investing in existing companies. We identify a promising therapeutic opportunity and build the company to advance it, uniting the asset, leadership, development strategy, and financing. As a family office, we have the flexibility to take a more patient approach than a traditional venture capital firm because we are not accountable to outside fund investors or constrained by a conventional fund timeline. That patience must still be paired with disciplined judgment and clear milestones. Capital is essential, but it is only one part of our contribution.

Our physician-led perspective is fundamentally about people, judgment, and direct interaction. In medicine, a careful history and physical examination can provide 70 to 80 percent of the information needed to understand a patient. I believe the same principle applies to company building: there is no substitute for getting to know the people, asking the right questions, and applying experienced judgment. We begin with the unmet medical need and evidence of a therapy’s potential, focusing on clinically ready assets. We then assess the regulatory pathway and commercial opportunity together, asking what it will take to develop the medicine and bring it to patients.

We remain hands-on throughout the process, recruiting experienced executives, shaping strategy and governance, and working with investment partners to finance development. That level of involvement across multiple portfolio companies is possible because I have spent more than 30 years building professional networks and human capital. Those relationships help us bring the right people and expertise together when a company needs them. We do more than select investments and monitor progress. We help create the conditions for success, with the goal of meaningful patient benefit and long-term investor value.

Bench2Bedside: Your background spans medicine, pharmaceutical development, and finance. What led you to establish EGB Ventures, and how does your experience as a physician shape the scientific opportunities you choose to pursue?

William Garner: My career has shown me how science, product development, and financing must inform one another. As a physician, I begin by asking what problem a therapy could solve, where current care falls short, and whether the evidence supports a meaningful improvement for patients.

We look for a strong biological rationale supported by translational evidence and, where available, prior clinical or other development data. Some of the most interesting opportunities are overlooked drugs or assets with existing evidence that has not yet been fully translated into a viable development program. That does not eliminate development risk, but it helps us make informed decisions about which opportunities to pursue. The science must be compelling, and there must also be a practical path to developing a treatment that matters to patients.

Bench2Bedside: Once EGB Ventures decides to form a company around a therapeutic opportunity, how do you determine the leadership, development plan, governance, and financing needed to reach its first value-creating milestones?

William Garner: We work backward from the next meaningful development decision. What evidence would justify advancing the asset, attracting a partner, or supporting the next financing? Depending on the program, that could mean establishing a dose, generating an initial efficacy signal, or clarifying the regulatory pathway.

Those objectives determine the expertise we need. We recruit leaders with experience relevant to the company’s next stage and establish a board that can provide informed oversight, challenge assumptions, and hold management accountable.

The financing plan follows the development plan. It needs to fund the work required to reach meaningful milestones, with flexibility for delays or unexpected findings. Each element should support the same objectives so the company can make decisions based on evidence.

Bench2Bedside: Many promising therapies stall when scientific, operational, and financing decisions are not aligned. How do you keep portfolio companies focused on the milestones that matter most?

William Garner: The challenge is maintaining discipline as new data emerge and circumstances evolve. We encourage teams to evaluate each activity against a clear question: Will this work help us make an important clinical, regulatory, or business decision?

That requires ruthlessly prioritizing the studies and activities that will answer the most important questions, while setting aside work that may be scientifically interesting but does not advance the program. It also means reviewing assumptions as evidence develops and adjusting priorities when necessary.

Close coordination among management, scientific and clinical advisers, the board, and investors help keep expectations realistic. A milestone is useful when it informs what happens next, not simply because it appears on a timeline. Our role is to help companies maintain that focus and use their resources effectively.

Bench2Bedside: EGB Ventures sources therapeutic opportunities globally and builds companies across markets, including Australia. How do differences in development costs, nondilutive funding, investor access, and public-market valuations influence where you form and finance a company?

William Garner: We look at where each part of the development process can be carried out most effectively. The best location for clinical research may differ from the best market for raising capital or ultimately commercializing a therapy. Our goal is to connect those advantages into a coherent strategy. Importantly, when establishing a company in Australia, there must always be a genuine Australian nexus, grounded in substantive research, development, operations, or other meaningful activity rather than simply seeking a financial or structural advantage.

Australia offers experienced clinical investigators, an efficient Clinical Trial Notification framework, and R&D incentives that can reduce eligible development costs without diluting shareholders. Its planned national clinical trials platform could further streamline ethics and site approvals. Together, those features can help companies stretch their capital and generate evidence needed to support further development or partnering. However, proposed changes to the R&D Tax Incentive underscore why we must evaluate policy stability alongside immediate financial benefits.

On the financing side, we consider investor appetite, access to follow-on capital, and whether public-market valuations fairly reflect an asset’s potential. A higher valuation alone is not enough. The company needs investors who understand its development strategy and can support it through value-building milestones. We also consider how Australian clinical capabilities can complement U.S. investor access, infrastructure, and commercial opportunities.

Ultimately, where we form, develop, and finance, a company should serve the therapeutic program. The objective is to generate credible clinical evidence efficiently while maintaining the resources and flexibility needed to advance toward patients.

Bench2Bedside: Entropy Neurodynamics and Island Pharmaceuticals operate in different therapeutic areas. What do their development strategies reveal about the common principles EGB Ventures applies across its portfolio, and which upcoming milestones will best demonstrate whether those principles are working?

William Garner: Entropy Neurodynamics and Island Pharmaceuticals illustrate our approach to building companies around therapeutic opportunities with a scientific foundation and significant unmet need.

Entropy is advancing TRP-8803, an intravenous psilocin formulation designed to give clinicians greater control over the onset, intensity, and duration of psychedelic treatment. Recent updates have highlighted its 12-week binge eating disorder results and plans for a U.S. depression trial. What interests me is the opportunity to combine evidence of therapeutic benefit with a delivery approach designed for more controlled administration in clinical practice.

Island is developing two antiviral programs: ISLA-101 for dengue and other mosquito-borne diseases, and galidesivir for serious viral threats, including Ebola and Marburg. Galidesivir also illustrates the kind of overlooked opportunity we seek. For certain serious or life-threatening conditions where human efficacy trials are not ethical or feasible, the FDA’s Animal Rule can allow efficacy to be demonstrated through adequate and well-controlled animal studies, alongside other required evidence, to support approval. That potential regulatory pathway is particularly significant for treatments targeting rare but dangerous viral threats. The company recently announced that it had secured pivotal Marburg data to support galidesivir’s FDA pathway and, on October 2, commenced GMP manufacturing. Those are important steps in building the evidence and manufacturing capabilities needed to advance the program.

The common principle is translating existing evidence into a focused development program. These companies face different scientific and operational challenges, but both must generate the data needed to justify their next steps. That measurable progress is what makes their work exciting to me.